Background: Selective embolization therapy (SET) has been employed to treat a number of malignant tumors, but experience with its use in metastatic epithelial thyroid carcinoma (ETC) is limited. Here we report our experience with the effect of SET on symptoms and serum thyroglobulin (Tg) in patients with bone metastases from ETC. Methods: This was a retrospective study of 13 patients with bone metastases from ETC who underwent 65 embolizations for bone metastases in 43 sessions. In the treated patients, symptoms considered related to bone metastases were compared before and about 4-7 weeks after the embolization session. Embolization sessions were excluded for analysis if concomitant therapy had taken place within 4-7 weeks before and=or after the session. Serum Tg concentrations were employed as an index of tumor debulking by SET. We attempted to estimate the influence of SET on survival time in patients with disseminated ETC who did, and an historical control group of patients with disseminated ETC who did not receive SET. Results: After exclusion of 12 (of which 3 sessions failed) out of 43 sessions, clinical symptoms, such as pain, and neurological symptoms decreased after 17, increased after 6, and did not change after 8 procedures. In 43 sessions, 20 of which were excluded (including the 3 sessions that failed), serum Tg decreased after 14 and increased after 9. The median standardized survival time of the group that received embolization was not significantly different to that of the group that did not receive embolization. Conclusions: Embolization therapy does not appear to improve life expectancy, but in selected patients can achieve palliation of pain, prevent neurological damage, reduce tumor burden, and give devascularization of the tumor before surgery.
Introduction
A lthough overall survival in patients with epithelial thyroid carcinoma (ETC) is excellent, patients with persistent disease have a life expectancy of approximately 60% of the normal residual life span (1) . The challenge in treating this persistent disease is to improve survival and control symptoms such as pain and different neurological symptoms. Standard treatment consists of thyroidectomy followed by high-dose radioiodine and lifelong thyroid hormone suppression therapy. In cases of persistent disease, surgery and occasionally additional external beam therapy are used. Other treatments, including labeled octreotide, have limited results (2) .
Selective embolization therapy (SET) for the treatment of bone tumors was first described by Feldman et al. in 1975 (3) . Camille et al. (4) were the first to write about preoperative embolization therapy for thyroid carcinoma. They wrote about embolization of metastases from thyroid carcinoma before surgery in four cases with spinal or pelvic metastases.
Several case reports with embolization therapy in the treatment of thyroid cancer are described (5) (6) (7) (8) (9) (10) . Few reports, including one report written by our group, deal with embolization therapy for bone metastasis in thyroid cancer (11, 12) ; others concern direct embolization of the primary thyroid tumor (13, 14) or the use of embolization as a preoperative procedure (15) (16) (17) (18) . These reports indicated that some patients achieved a rapid reduction in pain and tumor burden. Barton et al. (19) showed that embolization is generally an effective treatment for bone metastases of different primary tumors. It is known that embolization therapy together with antivascular therapy (Marimastat) has no additional effect for clinical symptoms (20) .
Previous studies have shown that clinical improvement was not always concordant with tumor regression on imaging (12) .
We report our experience with the effect of SET on symptoms and serum thyroglobulin (Tg) in patients with bone metastasis from ETC, and we investigate if SET has an additional value to life expectancy.
Materials and Methods
The University Medical Center Groningen is the major referral center in the northern part of The Netherlands for treatment of patients with ETC. The treatment regimen and follow-up were described earlier (21) and consisted of a total thyroidectomy and I-131 therapy, with Tg measurement under thyroxine suppression therapy after a negative posttherapeutic whole-body scan (WBS).
The patient group was consisted of 13 patients with disseminated ETC who received SET for their bone metastases to control pain, and=or to achieve tumor debulking, and in specific cases to obtain devascularization before surgery. An additional nonrandomized group of 87 patients with disseminated ETC who did not receive SET (No-SET group) was used to estimate the impact of SET on survival. Between 1996 and 2006 the 13 SET-treated patients underwent 65 embolizations in 43 sessions. Eleven of these patients had persistent disease after initial therapy, and nine of them presented with only bone metastases. The other two patients were in remission after initial treatment, but developed recurrent persistent disease with bone metastases. The SET procedures were executed after obtaining informed consent.
The 87 patients in the No-SET group were part of the large cohort that has been described earlier (1) . Sixty-seven of these patients had persistent disease after their initial surgical and radioiodine treatment, and 20 patients developed recurrent disease after this initial treatment and did not have a second remission after the additional treatment.
Regarding terminology, an embolization session refers to several embolizations in one patient on the same day, and an embolization refers to one embolization procedure.
The success of embolization was evaluated by additional angiography after the embolization session. After 3-4 months the success of the embolization was measured by magnetic resonance imaging and computed tomography. Embolizations that were at least 60% complete were considered partially successful, and embolizations that were 100% complete were considered completely successful.
Completely and partially successful embolizations were included in the analysis unless there was concomitant therapy near the time of the procedure. In 43 embolization sessions during which 65 embolizations were administered, 48 embolizations were successful, 13 embolizations were partially successful, and 4 embolizations were not successful. To evaluate the effect of therapy (symptoms and Tg levels), no concomitant therapies in a period of 4-7 weeks before and after the embolization sessions were accepted for evaluation. Therefore, nine embolization sessions were excluded because of concomitant surgery (four sessions and four embolizations), antivascular therapy (three sessions and eight embolizations), and I-131 therapy (two sessions and two embolizations). In eight other embolization sessions no Tg levels were available. Of the total 12 and 20 embolization sessions that were excluded, both contained the 4 embolizations executed in 3 sessions that failed. In sum, 23 embolization sessions were evaluable for Tg levels and 31 sessions for symptoms.
Persistent disease after initial therapy was defined as clinical evidence of thyroid cancer found at any visit after ablation. Recurrent disease was defined as tumor recurrence indicated by newly detectable Tg during suppression therapy or clinical evidence of disease detected by other technique. The characteristics of the SET and non-SET groups are given in Table 1 . Both groups were compared for differences in survival. Most of the patients in the embolization group have follicular thyroid carcinoma and M1 tumors for metastases. For survival, both subgroups of patients were also compared separately with the same subgroup in the control group.
Laboratory methods
Serum Tg was measured by a commercially available radioimmunoassay (Cis Bio International, Gif-sur-Yvette, France), with a lower detection limit of 1.5 ng=mL. In cases of an undetectable serum Tg, the presence of Tg antibodies was evaluated by recovery of added standard Tg. Tg antibodies were considered to be absent if recovery was >85%. None of our patients had Tg antibodies.
After March 2004 the Tg-immunochemiluminometric assay was determined (the Nichols Advantage Ò Tg assay; Nichols Institute Diagnostics, San Clemente, CA), detection limit <0.6 ng=mL, and antibodies by the Nichols Advantage TgAb assay (Nichols Institute Diagnostics) with a cutoff value for TgAb positivity of 2 mIU=L were introduced (22) .
Embolization technique
Before embolization, all the tumor-supplying vessels were visualized by diagnostic angiography. Embolization was performed during the same session. A no. 6 French (F) sheath was placed into the femoral artery, to facilitate catheter exchange. Then a 6 F guiding catheter (Boston Scientific, Natick, MA) was inserted proximal in the main tumor-feeding artery. With a microcatheter (Excel 14; Boston Scientific) a superselective microcatheterization of the tumor vessels was 
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DE VRIES ET AL. Table 2 . With additional angiography, the direct result of the embolization session was documented. For the detection of side effects, including the postembolization syndrome as flu-like symptoms or fever (11) and technical complications, all patients in whom embolization was performed were clinically observed during 24-48 hours.
Effect of therapy
The effect of the therapy was evaluated by clinical complaints such as pain, mobility, insensibility, and Tg levels. These data were collected from the patient charts retrospectively.
Clinical complaints of the local metastases were categorized as regression, stabilization, or progression. The clinical complaints before the embolization session were compared with those about 4-7 weeks after the embolization session.
Tg was measured 3 weeks before (range, 0-136 days) and up to 7 weeks after (range, 10-164 days) embolization during thyroid-stimulating hormone suppression. The individual standardized survival time was calculated as the ratio between the observed survival time of an individual and the median residual life span of the individuals with the same age in the general population in the year of diagnosis as described earlier (1).
Statistical analysis
Differences in standardized survival were analyzed by log rank test. Continuous variables are given as mean with SD; differences were tested by Mann-Whitney U-test. Differences in prevalences were tested by chi-square test. Changes in subjective complaints and Tg concentrations were tested by sign-test. p-Values less than 0.05 were considered significant. Table 1 shows the characteristics of the SET and No-SET groups. More females were present in the embolization group, but age was comparable in both groups. The prevalence of distant metastases at diagnosis was significantly higher in the SET group ( p < 0.0005) than in the No-SET group, and positive regional nodes were not present at diagnosis ( p < 0.005). There were significantly more ( p < 0.0003) follicular thyroid carcinomas in the SET group than in the No-SET group. Twelve patients in the SET group had follicular thyroid carcinoma; one patient (no. 10) had Hü rthle cell carcinoma. Table 3 shows the characteristics of individual patients, the number of embolizations, their locations, and additional 
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therapies. Eight patients in the SET group were locally treated with external beam therapy; five of these patients had this therapy before the embolization session. The mean time of external beam therapy before an embolization session was 10.5 months with a range of 1.5-20.5 months. Of the 13 embolizations that partially succeeded and the four embolizations that failed, external beam therapy was not given before embolization. Figure 1 shows the angiogram made before the embolization session. In Figure 2A and B the situation before and after embolization of the left side is visible after finishing the right side of L3. Indications for embolization were tumor debulking before I-131 therapy (42.5%), preventing neurological damage (35%), diminishing complaints of pain (45%), and embolization before debulking surgery (10%). In total the percentages are more than 100% because some embolization procedures had more indications.
Pre-and post-SET symptomology in patients with successful embolizations
Symptoms of patients comprised pain and neurological symptoms, like numbness, tingling, or radicular pain. Symptoms decreased during 17 sessions, were unchanged during 8 sessions, and increased during 6 sessions ( p < 0.01). The duration of improvement after these 17 sessions had a mean duration of 8.1 months with a range of 0.2-36 months. The most effective embolizations were performed at the first session. Most of the patients of whom the symptoms were unchanged after the session did not have complaints before the embolization session. a Age: at initial diagnosis (from duration of illness). T, tumor; N, nodes; M, metastases.
FIG. 1.
Angiogram before the embolization session of patient 11 (anteoposterior projection). Selective catheterization of the feeding lumbar artery on the left side shows a blush in the metastase of the 3 rd lumbar vertebra (L3).
Tg levels
In 23 of the 43 embolization sessions Tg levels were evaluable. Before embolization Tg levels ranged from 18 to 18,200 ng=mL, and afterward from 13 to 37,400 ng=mL (Table  4) . After the embolization, serum Tg levels decreased in 14 procedures (mean change, 1015 ng=mL) and increased in 9 procedures (mean change, 4932 ng=mL, not significant). The greatest changes in serum Tg after embolization were noted in patients with the higher serum Tg concentrations (Table 4) .
Of the 14 patients who had a decrease in Tg level, 8 patients had symptomatic relief, 4 patients did not feel difference in their complaints, and 2 patients had an increase of symptomatic complaints. Of the nine patients who had an increase in Tg level, four patients had symptomatic relief, two patients did not feel difference in their complaints, and three patients had an increase of symptomatic complaints.
Survival time in SET and non-SET patients
The survival expressed as median standardized survival time was not significantly different between the SET group, which was 0.43 (95% confidence interval [CI], 0.24-0.63), and the non-SET group, which was 0.56 (95% CI, 0.39-0.74).
Comparison of the patients with follicular thyroid cancer separately showed no significant difference, 0.42 (95% CI, 0.04-0.80), in the survival between the patients with embolization therapy and the patients of the control group. Comparison of the standardized survival of the 13 patients from the embolization group with the 23 patients from the control group with M1 tumors also showed no difference, 0.42 (95% CI, 0.0-0.95).
Complications
During the first five embolization sessions no steroid coverage was added, and several minor complications occurred 
Discussion
Our series illustrated that embolization therapy can achieve palliation of pain and prevent neurological damage in a substantial number of patients with bone metastases from epithelial cell thyroid cancer, but in contrast to radical surgical removal of bone metastases (23) , embolization therapy does not appear to improve survival. Based on serum Tg measurements taken weeks after this therapy, it appears that more than half of treated patients achieved a reduction of tumor burden. Life expectancy, however, is probably not influenced by embolization therapy. The changes in serum Tg after embolization therapy were highly variable, but a decrease was noted more often than an increase.
When embolization therapy was successful or partially successful, in 61% there was a decrease of the serum Tg level. To minimize a possible long-lasting effect of other treatments, we used in our analysis only those embolization sessions for patients who had received no additional therapy 28-49 days before and for the same period after their embolization sessions. It should be noted that the half-life of Tg in the circulation is 4 hours to 4 days (24) (25) (26) . Therefore, as serum Tg was measured at least 10 days after embolization therapy, it seems unlikely that serum Tg reflected acute necrosis of infarcted tumor tissue. Our data suggest that Tg is a weak indicator of tumor necrosis after embolization. Embolization therapy appears to be beneficial in two ways. First, it appears to improve the quality of life in some patients. This is particularly important because the survival of patients with metastatic differentiated thyroid cancer (DTC) is relatively long. This conclusion is also supported by the study of Eustatia-Rutten et al. (12) . They noted that a substantial percentage of patients had improvement in clinical symptoms after embolization therapy, although some of these patients did not have tumor regression scored by Tg level and=or imaging. In another study of four patients, Smit et al. (9) noted dramatic relief of neurological symptoms after embolization therapy of vertebral metastasis from differentiated follicular thyroid carcinoma. In a third study of Van Tol et al. (11) , there was improvement of symptoms in patients treated with embolization and radioiodine therapy, but this improvement was not significantly different compared to patients treated with radioiodine therapy alone. The present study is a larger one than our early preliminary study (11) of five patients with bone metastasis due to DTC. In that study, radioiodine therapy alone or radioiodine therapy combined with embolization therapy was used, and there was a significantly greater decrease in serum Tg in patients when the combination of embolization and radioiodine therapy was employed than radioiodine alone. In the current larger series we conclude that embolization therapy is beneficial in a substantial number of patients. In our patients, the clinical symptoms were evaluable in 31 embolization procedures. A decrease of clinical complaints was found in 55%. Embolization therapy has been shown to be a safe and effective noninvasive procedure, which in this study is confirmed by the low treatment failure of only four embolizations, and can be combined with all other treatment options, and complications are not common (11, 12) .
The second advantage of embolization therapy is that it can be used to prepare selected patients for surgery of the targeted metastatic lesion. This was done in four of our patients. Metastatic thyroid lesions, especially in bones, are hypervascular. By means of preoperative embolization, the intraoperative blood loss can be reduced (10) , as has been shown in metastatic renal cell carcinomas (27) .
Irradiated metastases can also be embolized to decrease local tumor progression. Five patients in our series had been irradiated before embolization therapy, and this did not make the procedure more difficult.
The present study was not designed to determine the effect of SET on life expectancy because there were important clinical differences between SET and non-SET patients. Based on a comparison of these groups, however, it seems unlikely that SET has an important impact on life expectancy. This is not surprising because, for the most part, SET only targets a portion of the tumor burden. It is also consistent with other reports regarding SET as a treatment for thyroid and other cancers. Wirbel et al. (28) reported that preoperative embolization of spinal and pelvic metastases of different primary tumors, mostly renal cell carcinoma, had no influence on survival time. In the study of Bernier et al. (29) , 34 of 109 (31%) patients with DTC received selective arterial embolization therapy as preoperative and=or palliative treatment for bone metastases. No improvement in survival was noted. In the future, specific systemic treatment modalities for patients with DTC and hematological spread disease might possibly be more effective to improve survival. For improvement of survival, an aggressive multidisciplinary approach has been advocated (30), but local therapies for tumor control, like embolization therapy, are very valuable to the preservation of quality of life.
In conclusion, life expectancy in patients with metastatic disease is not improved by embolization therapy, but a significant effect on complaints and reduction of tumor burden was found. Embolization therapy can be used for tumor debulking, devascularization of tumor before surgery, and pain reduction, and can be combined with other treatment modalities such as radiation.
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